Millipore Sigma Vibrant Logo

05-23-0101 Angiotensin II, Human - CAS 4474-91-3 - Calbiochem

Plays an important role in the regulation of blood pressure.

FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: DRVYIHPF

Primary Target: adenylate cyclase activity
View Products on Sigmaaldrich.com
05-23-0101
  
Prix en cours de récupération
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
Maximum Quantity is
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
—
Demander le prix
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

       

      Contacter le Service Clients

      Aperçu

      Replacement Information

      Tableau de caractéristiques principal

      CAS #Empirical Formula
      4474-91-3C₅₀H₇₁N₁₃O₁₂
      Description
      OverviewPlays an important role in the regulation of blood pressure. Stimulates the release of aldosterone from the adrenal gland. Inhibits adenylate cyclase activity in spontaneously hypertensive rats. Has strong vasoconstrictive effects. Increases the entry of Ca2+ in heart muscle via voltage-sensitive channels and activates myosin light chain kinase. Also elicits an increase in voltage-dependent delayed rectifier K+ current in neurons. Activates JAK2 in smooth muscle cells. Activates p125FAK and a cytosolic 115-120 kDa calcium-dependent tyrosine kinase in rat epithelial cells. Also activates p60c-src as well as ERK1/2, JNK, and p38 MAP Kinase in vascular smooth muscle cells.
      Catalogue Number05-23-0101
      Brand Family Calbiochem®
      SynonymsDRVYIHPF
      References
      ReferencesZhu, M., et al. 2000. J. Neurophysiol. 84, 2494.
      Natarajan, R., et al. 1999. Hypertension 33, 378.
      Mazzolai, L., et al. 1998. Hypertension 31, 1324.
      Earp, H.S., et al. 1995. J. Biol. Chem. 270, 28440.
      Ishida, M., et al. 1995. Circ. Res. 77, 1053.
      Vyas, S.J., and Jackson, E.K. 1995. J. Pharmacol. Exp. Ther. 273, 768.
      Product Information
      CAS number4474-91-3
      ATP CompetitiveN
      FormWhite to off-white solid
      Hill FormulaC₅₀H₇₁N₁₃O₁₂
      Chemical formulaC₅₀H₇₁N₁₃O₁₂
      Hygroscopic Hygroscopic
      ReversibleN
      Sold on the basis of peptide contentY
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetadenylate cyclase activity
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableN
      Peptide ContentY
      Peptide SequenceH-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSBW2165000
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 week at 4°C or for up to 1 month at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      05-23-0101 0

      Documentation

      Required Licenses

      Title
      PRODUCTO REGULADO POR LA SECRETARÍA DE SALUD

      Angiotensin II, Human - CAS 4474-91-3 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Angiotensin II, Human - CAS 4474-91-3 - Calbiochem Certificats d'analyse

      TitreNuméro de lot
      05-23-0101

      Références bibliographiques

      Aperçu de la référence bibliographique
      Zhu, M., et al. 2000. J. Neurophysiol. 84, 2494.
      Natarajan, R., et al. 1999. Hypertension 33, 378.
      Mazzolai, L., et al. 1998. Hypertension 31, 1324.
      Earp, H.S., et al. 1995. J. Biol. Chem. 270, 28440.
      Ishida, M., et al. 1995. Circ. Res. 77, 1053.
      Vyas, S.J., and Jackson, E.K. 1995. J. Pharmacol. Exp. Ther. 273, 768.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision12-May-2008 JSW
      SynonymsDRVYIHPF
      DescriptionFunctions in blood pressure maintenance. Stimulates the release of aldosterone from the adrenal gland. Has strong vasoconstrictive effects. Increases the entry of Ca2+ in heart muscle via voltage-sensitive channels and activates myosin light chain kinase. Activates JAK2 in smooth muscle cells. Activates p125FAK and a cytosolic 115-120 kDa calcium-dependent tyrosine kinase in rat epithelial cells. Also activates pp60c-src in vascular smooth muscle cells. Inhibits adenylate cyclase activity in spontaneously hypertensive rats.
      FormWhite to off-white solid
      CAS number4474-91-3
      RTECSBW2165000
      Chemical formulaC₅₀H₇₁N₁₃O₁₂
      Peptide SequenceH-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH
      Purity≥98% by HPLC
      Solubility5% acetic acid (1 mg/ml) or H₂O (1 mg/ml)
      Storage -20°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 week at 4°C or for up to 1 month at -20°C.
      Toxicity Standard Handling
      Merck USA index14 651
      ReferencesZhu, M., et al. 2000. J. Neurophysiol. 84, 2494.
      Natarajan, R., et al. 1999. Hypertension 33, 378.
      Mazzolai, L., et al. 1998. Hypertension 31, 1324.
      Earp, H.S., et al. 1995. J. Biol. Chem. 270, 28440.
      Ishida, M., et al. 1995. Circ. Res. 77, 1053.
      Vyas, S.J., and Jackson, E.K. 1995. J. Pharmacol. Exp. Ther. 273, 768.